Compare RAMP & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAMP | MLTX |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1994 | 2020 |
| Metric | RAMP | MLTX |
|---|---|---|
| Price | $37.71 | $18.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $35.60 | $27.50 |
| AVG Volume (30 Days) | 1.3M | ★ 1.3M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22500.00 | N/A |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $812,940,000.00 | N/A |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $9.09 | N/A |
| P/E Ratio | $16.84 | ★ N/A |
| Revenue Growth | ★ 9.03 | N/A |
| 52 Week Low | $21.71 | $5.95 |
| 52 Week High | $37.92 | $62.75 |
| Indicator | RAMP | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.61 | 49.10 |
| Support Level | $37.25 | $15.54 |
| Resistance Level | $37.92 | $19.24 |
| Average True Range (ATR) | 0.19 | 1.12 |
| MACD | -0.24 | -0.11 |
| Stochastic Oscillator | 78.69 | 22.78 |
LiveRamp Holdings Inc is a technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics, and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust. The Company provides a data collaboration platform, essentially acting as a data collaboration hub where businesses can securely share and manage first-party consumer data with trusted partners while prioritizing data privacy and ethics.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.